Literature DB >> 25989953

Treatment of Unfit Patients With Advanced Non-Small-Cell Lung Cancer: Definition Criteria According an Expert Panel.

Filippo De Marinis1, Emilio Bria2, Paul Baas3, Marcello Tiseo4, Andrea Camerini5, Adolfo Gino Favaretto6, Cesare Gridelli7.   

Abstract

The assessment of special categories of non-small-cell lung cancer (NSCLC) patients requires a comprehensive analysis of all factors potentially influencing the daily quality of life and the relative contribution of tumor-related symptoms on the overall patient health status. While for elderly patients prospective evidence and recommendations allow clinicians to better address their patients to a shared treatment, a paucity of reliable data refers to treatment opportunities for these patients, termed frail or unfit, who are not considered eligible for chemotherapy usually administered to adult patients. This consensus was inspired by the absence of clear criteria to define the category of unfit patients in the context of advanced NSCLC in order to share all the available tools for their classification and evaluation and to support decisions for clinical practice on a daily basis. After review of the literature and panelist consensus, a series of items was identified as relevant: age, performance status, renal function, heart failure, previous cerebrovascular events, uncontrolled hypertension, neuropathy, hearing loss, symptomatic brain metastases, severe psychiatric disorders, and absence of caregiver support. On the basis of these factors, a treatment algorithm for clinical practice to categorize unfit NSCLC patient into 3 major clinical scenarios was defined: (1) unfit for cisplatin-based chemotherapy, (2) unfit for carboplatin-based chemotherapy, and (3) unfit for single-agent chemotherapy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Lung cancer; Review; Treatment; Unfit

Mesh:

Year:  2015        PMID: 25989953     DOI: 10.1016/j.cllc.2015.04.008

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  8 in total

1.  MicroRNA-216b regulated proliferation and invasion of non-small cell lung cancer by targeting SOX9.

Authors:  Sida Liu; Han Dong; Hui Dai; Danwei Liu; Zhihao Wang
Journal:  Oncol Lett       Date:  2018-04-25       Impact factor: 2.967

2.  SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.

Authors:  Michael Mark; Patrizia Froesch; Eric Innocents Eboulet; Alfredo Addeo; Miklos Pless; Sacha I Rothschild; Wolf-Dieter Janthur; Henning Burmeister; Alex Friedlaender; Martina Schneider; Yannis Metaxas; Markus Joerger; Luciano Wannesson; Michael Schwitter; Nathalie Baudoux; Susanne Weindler; Christine Biaggi-Rudolf; Martin Früh
Journal:  Cancer Immunol Immunother       Date:  2020-11-01       Impact factor: 6.968

Review 3.  Hydrogen Sulfide Biology and Its Role in Cancer.

Authors:  Saadullah Khattak; Mohd Ahmar Rauf; Nazeer Hussain Khan; Qian-Qian Zhang; Hao-Jie Chen; Pir Muhammad; Mohammad Azam Ansari; Mohammad N Alomary; Muhammad Jahangir; Chun-Yang Zhang; Xin-Ying Ji; Dong-Dong Wu
Journal:  Molecules       Date:  2022-05-25       Impact factor: 4.927

4.  MiR-613 induces cell cycle arrest by targeting CDK4 in non-small cell lung cancer.

Authors:  Duo Li; Dong-Qiong Li; Dan Liu; Xiao-Jun Tang
Journal:  Cell Oncol (Dordr)       Date:  2016-01-07       Impact factor: 6.730

5.  Restoration of CBX7 expression increases the susceptibility of human lung carcinoma cells to irinotecan treatment.

Authors:  Nunzio Antonio Cacciola; Romina Sepe; Floriana Forzati; Antonella Federico; Simona Pellecchia; Umberto Malapelle; Alfonso De Stefano; Danilo Rocco; Alfredo Fusco; Pierlorenzo Pallante
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-07-28       Impact factor: 3.000

6.  Intrapleural targeted therapies (anti-VEGF and anti-EGFR) in the model of malignant pleural effusion.

Authors:  Milena Marques Pagliarelli Acencio; Juliana Puka; Vanessa Adélia Alvarenga; Vanessa Martins; Mariana Lombardi Peres de Carvalho; Evaldo Marchi; Vera Luiza Capelozzi; Lisete Ribeiro Teixeira
Journal:  Oncotarget       Date:  2017-09-28

Review 7.  Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy.

Authors:  Sandro V Porceddu; Florian Scotté; Matti Aapro; Satu Salmio; Ana Castro; Vincent Launay-Vacher; Lisa Licitra
Journal:  Front Oncol       Date:  2020-01-22       Impact factor: 6.244

8.  nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis.

Authors:  Corey J Langer; Ajeet Gajra; Cesare Gridelli; Kartik Konduri; Daniel Morgensztern; David Spigel; Denis Talbot; Michael Thomas; Jared Weiss; Richard Pilot; Rafia Bhore; Marianne Wolfsteiner; Teng Jin Ong; Mark Socinski
Journal:  Front Oncol       Date:  2021-01-26       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.